RXRX Stock Price, Recursion Pharmaceuticals, . Quote, Chart

Market Summary

USD7.94+0.24

Market Closed

3.12%

RXRX Alerts

3 major insider sales recently.

RXRX Stock Price

View Fullscreen

RXRX RSI Chart

RXRX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

41.73

EV/EBITDA

-4.77

Price/Free Cashflow

-6.21

RXRX Price/Sales (Trailing)

RXRX Profitability

EBT Margin

-745.10%

Return on Equity

-70.79%

Return on Assets

-50.19%

Free Cashflow Yield

-16.11%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

44.6M

Rev. Growth (Yr)

-20.36%

Rev. Growth (Qtr)

3.4%

RXRX Earnings

Earnings (TTM)

-328.1M

Earnings Growth (Yr)

-61.75%

Earnings Growth (Qtr)

0.02%

Breaking Down RXRX Revenue

Last 7 days

6.3%

Last 30 days

-24.6%

Last 90 days

-22.4%

Trailing 12 Months

53.6%

How does RXRX drawdown profile look like?

RXRX Financial Health

Current Ratio

4.7

RXRX Investor Care

Shares Dilution (1Y)

22.64%

Diluted EPS (TTM)

-1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	46.6M	50.0M	47.4M	44.6M
2022	12.9M	18.1M	28.7M	39.8M
2021	25.2M	8.8M	10.3M	10.2M
2020	2.7M	3.1M	3.6M	4.0M
2019	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Recursion Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	secora michael	acquired	83,250	2.22	37,500	chief financial officer
Apr 17, 2024	secora michael	sold	-175,349	7.583	-23,124	chief financial officer
Apr 16, 2024	borgeson blake	sold	-87,725	7.6636	-11,447	-
Apr 16, 2024	secora michael	acquired	83,250	2.22	37,500	chief financial officer
Apr 16, 2024	secora michael	sold	-191,658	7.6663	-25,000	chief financial officer
Apr 04, 2024	gibson christopher	sold	-225,500	9.02	-25,000	chief executive officer
Apr 04, 2024	gibson christopher	sold	-360,800	9.02	-40,000	chief executive officer
Apr 04, 2024	gibson christopher	acquired	-	-	25,000	chief executive officer
Apr 03, 2024	gibson christopher	gifted	-	-	-25,000	chief executive officer
Apr 03, 2024	gibson christopher	acquired	-	-	25,000	chief executive officer

Which funds bought or sold RXRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Cherry Creek Investment Advisors, Inc.	added	222	397,802	573,833	0.31%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.71	-71,000	47,000	-%
Apr 23, 2024	WESBANCO BANK INC	new	-	650,044	650,044	0.03%
Apr 23, 2024	Global Retirement Partners, LLC	added	400	11,727	14,955	-%
Apr 23, 2024	Values First Advisors, Inc.	added	4.95	35,710	619,470	0.36%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	647,392	647,392	-%
Apr 22, 2024	WEALTH EFFECTS LLC	new	-	149,550	149,550	0.06%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	375,331	375,331	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	159,475	711,507	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	13.00	1,197	-%

Are Funds Buying or Selling RXRX?

Are funds buying RXRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RXRX

No. of Funds

RXRX Alerts

3 major insider sales recently.

Unveiling Recursion Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.52%	15,665,210	SC 13G/A
Feb 12, 2024	ark investment management llc	11.08%	23,076,052	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 29, 2024	blackrock inc.	6.0%	12,393,872	SC 13G/A
Jan 29, 2024	ark investment management llc	9.92%	20,654,287	SC 13G
Jan 26, 2024	baillie gifford & co	11.61%	24,179,504	SC 13G/A
Jan 24, 2024	state street corp	5.83%	12,151,646	SC 13G
May 22, 2023	kinnevik ab (publ)	5.6%	10,405,668	SC 13G
Feb 14, 2023	lux capital management, llc	3.3%	6,004,722	SC 13G/A
Feb 09, 2023	vanguard group inc	5.54%	10,057,363	SC 13G

Recent SEC filings of Recursion Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 18, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144/A	144/A
Apr 16, 2024	8-K	Current Report

Peers (Alternatives to Recursion Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Recursion Pharmaceuticals, Inc. News

Latest updates

Recursion Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	3.4%	10,891,000	10,533,000	11,017,000	12,134,000	13,676,000	13,160,000	7,674,000	5,333,000	2,533,000	2,534,000	2,549,000	2,562,000	2,691,000	1,025,000	18,943,000	-	-
Costs and Expenses	-0.2%	109,821,000	110,083,000	92,732,000	81,999,000	74,658,000	75,733,000	73,865,000	61,314,000	67,493,000	48,936,000	43,478,000	33,046,000	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	67,493,000	48,936,000	43,478,000	33,046,000	28,272,000	23,499,000	18,403,000	18,403,000	-
S&GA Expenses	4.3%	30,458,500	29,199,000	28,290,000	22,874,000	19,838,000	19,488,000	21,199,000	21,074,000	19,201,000	15,690,000	13,854,000	8,937,000	7,574,000	6,964,000	5,159,000	5,561,000	-
R&D Expenses	-0.7%	69,482,000	70,007,000	55,060,000	46,677,000	43,980,000	40,836,000	38,439,000	32,441,000	48,292,000	33,246,000	29,624,000	24,109,000	20,698,000	16,535,000	13,244,000	12,842,000	-
EBITDA Margin	-Infinity%	-6.90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	445.5%	60,000	11,000	12,000	13,000	13,000	14,000	14,000	14,000	15,000	125,000	286,000	254,000	166,000	101,000	416,000	306,000	-
EBT Margin	-Infinity%	-7.45	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	0.0%	-92,996,000	-93,017,000	-76,726,000	-65,327,000	-57,492,000	-60,445,000	-65,560,000	-55,979,000	-64,933,000	-47,428,000	-43,401,000	-30,717,000	-25,766,000	-23,873,000	-18,943,000	-18,424,000	-
Net Income Margin	-19.1%	-7.36	-6.18	-5.20	-5.33	-6.01	-8.60	-12.94	-16.35	-18.32	-14.25	-14.02	-3.94	-21.96	-17.42	-19.70	-22.67	-26.68
Free Cashflow	-3.4%	-76,144,000	-73,665,000	-71,435,000	-78,491,000	-52,727,000	-62,804,000	-78,098,000	73,046,000	-65,622,000	-42,754,000	-39,865,000	-50,171,000	4,886,000	-20,282,000	-17,333,000	-18,501,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	3.6%	654	631	667	627	701	612	673	734	610	659	699	272	299
Current Assets	6.7%	438	411	431	492	570	482	546	619	535	601	648	222	266
Cash Equivalents	1.1%	392	387	406	473	550	465	464	518	295	405	643	219	267
Net PPE	0.3%	87.00	86.00	90.00	90.00	88.00	86.00	82.00	71.00	65.00	55.00	49.00	45.00	26.00
Goodwill	-1.3%	52.00	53.00	61.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	1.00
Liabilities	-1.3%	190	193	198	197	215	223	235	241	67.00	60.00	56.00	57.00	57.00
Current Liabilities	-1.0%	93.00	94.00	114	92.00	100	83.00	97.00	86.00	47.00	43.00	30.00	27.00	23.00
Shareholder's Equity	5.8%	463	438	469	430	486	388	438	494	543	599	643	-	-206
Retained Earnings	-10.6%	-967	-874	-781	-704	-639	-582	-521	-456	-400	-335	-287	-244	-213
Additional Paid-In Capital	9.0%	1,431	1,313	1,251	1,135	1,125	970	959	950	943	934	930	11.00	7.00
Shares Outstanding	8.3%	234	216	207	192	191	172	171	171	125	111	81.00	23.00	22.00
Float	-	-	-	930	-	-	-	941	-	-	-	3,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-1.6%	-74,077	-72,920	-67,467	-73,316	-44,748	-54,541	-61,623	77,388	-61,158	-33,048	-33,653	-30,755	8,573	-19,456	-16,699	-17,817	-
Share Based Compensation	-4.2%	16,086	16,792	11,811	8,814	7,695	8,907	5,675	5,632	4,341	3,363	5,317	1,821	1,188	1,070	769	1,265	-
Cashflow From Investing	-617.0%	-2,488	-347	-2,053	-5,340	-7,979	52,984	4,940	143,304	-52,243	-193,873	-6,212	-19,416	-4,591	-3,426	-39.00	-684	-
Cashflow From Financing	50.0%	80,659	53,765	3,787	1,922	147,256	2,337	2,668	2,084	3,796	-11,095	463,705	2,134	10,035	229,721	382	5,997	-

RXRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue
Revenue	$ 44,575	$ 39,843	$ 10,178
Operating costs and expenses
Cost of revenue	42,587	48,275	0
Research and development	241,226	155,696	135,271
General and administrative	110,822	81,599	57,682
Total operating costs and expenses	394,635	285,570	192,953
Loss from operations	(350,060)	(245,727)	(182,775)
Other income (loss), net	17,932	6,251	(3,704)
Loss before income tax benefit	(332,128)	(239,476)	(186,479)
Income tax benefit	4,062	0	0
Net loss	$ (328,066)	$ (239,476)	$ (186,479)
Per share data
Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)	$ (1.58)	$ (1.36)	$ (1.49)
Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)	$ (1.58)	$ (1.36)	$ (1.49)
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)	207,853,702	175,537,487	125,348,110
Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)	207,853,702	175,537,487	125,348,110
Operating revenue
Revenue
Revenue	$ 43,876	$ 39,681	$ 10,000
Grant revenue
Revenue
Revenue	$ 699	$ 162	$ 178

RXRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 391,565	$ 549,912
Restricted cash	3,231	1,280
Other receivables	3,094	2,753
Other current assets	40,247	15,869
Total current assets	438,137	569,814
Restricted cash, non-current	6,629	7,920
Property and equipment, net	86,510	88,192
Operating lease right-of-use assets	33,663	33,255
Intangible assets, net	36,443	1,306
Goodwill	52,056	801
Other assets, non-current	261	0
Total assets	653,699	701,288
Current liabilities
Accounts payable	3,953	4,586
Accrued expenses and other liabilities	46,635	32,904
Unearned revenue	36,426	56,726
Notes payable	41	97
Operating lease liabilities	6,116	5,952
Total current liabilities	93,171	100,265
Unearned revenue, non-current	51,238	70,261
Notes payable, non-current	1,101	536
Operating lease liabilities, non-current	43,414	44,420
Deferred tax liabilities	1,339	0
Total liabilities	190,263	215,482
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2023 and December 31, 2022; 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) and 191,022,864 (Class A 183,209,655 and Class B 7,813,209 and Exchangeable —) issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	2	2
Additional paid-in capital	1,431,056	1,125,360
Accumulated deficit	(967,622)	(639,556)
Total stockholders’ equity	463,436	485,806
Total liabilities and stockholders’ equity	$ 653,699	$ 701,288

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Dr. Christopher C. Gibson Ph.D.
WEBSITE	recursion.com
INDUSTRY	Biotechnology
EMPLOYEES	550

Recursion Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Recursion Pharmaceuticals, Inc.? What does RXRX stand for in stocks?

RXRX is the stock ticker symbol of Recursion Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Recursion Pharmaceuticals, Inc. (RXRX)?

As of Wed Apr 24 2024, market cap of Recursion Pharmaceuticals, Inc. is 1.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers. The fair value of Recursion Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Recursion Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Recursion Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXRX is over valued or under valued. Whether Recursion Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Recursion Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXRX.

What is Recursion Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, RXRX's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 41.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXRX PE ratio will change depending on the future growth rate expectations of investors.